A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients

Cancer Research

Volumn 71, Issue 15, 2011, Pages 5255-5264

  Tiedt, Ralph ^a   Degenkolbe, Elisa ^a,c   Furet, Pascal ^a   Appleton, Brent A ^b   Wagner, Sabrina ^a   Schoepfer, Joseph ^a   Buck, Emily ^b,d   Ruddy, David A ^b   Monahan, John E ^b   Jones, Michael D ^b   Blank, Jutta ^a   Haasen, Dorothea ^a   Drueckes, Peter ^a   Wartmann, Markus ^a   McCarthy, Clive ^a,e   Sellers, William R ^b   Hofmann, Francesco ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Biovex Inc   (United States)

^e EVOTEC UK LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 HYDROXY 2 METHYLPROPYL) 5 METHYL 3 OXO 2 PHENYL 2,3 DIHYDRO 1H PYRAZOLE 4 CARBOXYLIC ACID; 6 [6 (1 METHYL 1H PYRAZOL 4 YL)IMIDAZO[1,2 B]PYRIDAZIN 3 YLMETHYL]QUINOLINE; AMG 458; ANTINEOPLASTIC AGENT; NVP BVU972; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER RESISTANCE; CELL POPULATION; CELL PROLIFERATION; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTALLIZATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; GENE ACTIVATION; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

AMINO ACID SUBSTITUTION; AMINOPYRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HUMANS; MICE; MODELS, MOLECULAR; MUTAGENESIS; MUTATION, MISSENSE; NEOPLASMS; POINT MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; QUINOLINES; RECEPTORS, GROWTH FACTOR; TYROSINE;

EID: 79960967335     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-4433     Document Type: Article

References (47)

1. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80. (Pubitemid 32743979)
2. O'Hare T, Eide CA, Deininger MW. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. Expert Opin Investig Drugs 2008;17:865-78. (Pubitemid 351864324)
3. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet 2007;369:1731-41. (Pubitemid 46778870)
4. Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 2007;110:4005-11. (Pubitemid 350248456)
5. Janne PA. Challenges of detecting EGFR T790M in gefitinib/ erlotinibresistant tumours. Lung Cancer 2008;60 Suppl 2:S3-9. (Pubitemid 351726031)
6. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003;112:831-43. (Pubitemid 36378885)
7. Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007;109:5011-5. (Pubitemid 46827801)
8. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 2009;106:20411-6.
9. Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006;108:2332-8. (Pubitemid 44497517)
10. O'Hare T, Eide CA, Tyner JW, Corbin AS, Wong MJ, Buchanan S, et al. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Natl Acad Sci U S A 2008;105:5507-12. (Pubitemid 351753893)
11. von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 2006;108:1328-33. (Pubitemid 44232032)
12. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-16. (Pubitemid 351767118)
13. Liu X, Newton RC, Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med 2009;16:37-45.
14. Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 2003;63:5462-9. (Pubitemid 37139865)
15. Furet P, McCarthy C, Schoepfer J, Spanka C, Stang M, Stauffer F inventors; Novartis AG (Lichtstrasse 35, Basel, CH-4056, CH), assignee. Imidazo [1,2-b] pyridazine derivatives for the treatment of c-Met tyrosine kinase mediated disease. WO/2009/106577. 2009.
16. Liu L, Siegmund A, Xi N, Kaplan-Lefko P, Rex K, Chen A, et al. Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl) -5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458). J Med Chem 2008;51:3688-91. (Pubitemid 351956499)
17. Kabsch W. XDS. Acta Crystallogr D Biol 2010;66:125-32.
18. Evans P. Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr 2006;62:72-82.
19. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr 2007;40:658-74. (Pubitemid 47080256)
20. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, et al. PHENIX: a comprehensive Python-based system for macro-molecular structure solution. Acta Crystallogr D Biol Crystallogr 2010;66:213-21.
21. Bricogne G, Blanc E, Brandl M, Flensburg C, Keller P, Paciorek W, et al. BUSTER, version 2.8.0. Cambridge, UK: Global Phasing Ltd;2009.
22. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 2010;66:486-501.
23. Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 2007;67:2081-8. (Pubitemid 46424226)
24. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 2006;103:2316-21. (Pubitemid 43271667)
25. Kim KS, Zhang L, Schmidt R, Cai ZW, Wei D, Williams DK, et al. Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities. J Med Chem 2008;51:5330-41.
26. Timofeevski SL, McTigue MA, Ryan K, Cui J, Zou HY, Zhu JX, et al. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry 2009;48:5339-49.
27. Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 2009;69:8009-16.
28. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73. (Pubitemid 27198158)
29. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999;18:2343-50. (Pubitemid 29192711)
30. Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, Stefani AD, et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000;19:1547-55. (Pubitemid 30175676)
31. Lorenzato A, Olivero M, Patane S, Rosso E, Oliaro A, Comoglio PM, et al. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res 2002;62:7025-30. (Pubitemid 35424097)
32. Wang W, Marimuthu A, Tsai J, Kumar A, Krupka HI, Zhang C, et al. Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase. Proc Natl Acad Sci U S A 2006;103:3563-8. (Pubitemid 43376595)
33. Boezio AA, Berry L, Albrecht BK, Bauer D, Bellon SF, Bode C, et al. Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors. Bioorg Med Chem Lett 2009;19:6307-12.
34. Buchanan SG, Hendle J, Lee PS, Smith CR, Bounaud PY, Jessen KA, et al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol Cancer Ther 2009;8:3181-90.
35. King P. JNJ-38877605: a selective oral c-Met inhibitor for the treatment of cancer [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 20; Exhibit Hall A-C, Poster Section 26. Washington (DC): AACR; 2010. Abstract nr 3628.
36. Porter J. Small molecule c-Met kinase inhibitors: a review of recent patents. Expert Opin Ther Pat 2010;20:159-77.
37. Albrecht BK, Harmange JC, Bauer D, Berry L, Bode C, Boezio AA, et al. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. J Med Chem 2008;51:2879-82. (Pubitemid 351706015)
38. Bellon SF, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K, et al. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem 2008;283:2675-83.
39. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borras AM, Gale CM, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 2006;116:2695-706. (Pubitemid 44511633)
40. Qi J, McTigue MA, Rogers A, Lifshits E, Christensen JG, Janne PA, et al. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res 2011;71:1081-91.
41. Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, Zeng Z, et al. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther 2008;7:3499-508.
42. McDermott U, Pusapati RV, Christensen JG, Gray NS, Settleman J. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res 2010;70:1625-34.
43. Cepero V, Sierra JR, Corso S, Ghiso E, Casorzo L, Perera T, et al. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res 2010;70:7580-90.
44. Corso S, Ghiso E, Cepero V, Sierra JR, Migliore C, Bertotti A, et al. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer 2010;9:121.
45. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43. (Pubitemid 46799492)
46. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010;17:77-88.
47. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008;68:9479-87.